Zegbeh Jallah
Stock Analyst at Capital One
(2.99)
# 1,420
Out of 4,947 analysts
24
Total ratings
36.36%
Success rate
120.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $2.34 | +4,173.50% | 2 | Dec 27, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $11.09 | +296.75% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $10.57 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $24.33 | +19.19% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $384 | $11.74 | +3,170.87% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $8.00 | +775.00% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $6.50 | +223.08% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $7.09 | +1,804.09% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.20 | +5,900.00% | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | $10 → $6 | $1.05 | +471.43% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $12.88 | +327.02% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.36 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.42 | +1,791.25% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $600 | $2.85 | +20,952.63% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $2.34
Upside: +4,173.50%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $11.09
Upside: +296.75%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $10.57
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $24.33
Upside: +19.19%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $384
Current: $11.74
Upside: +3,170.87%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $8.00
Upside: +775.00%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $6.50
Upside: +223.08%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $7.09
Upside: +1,804.09%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.20
Upside: +5,900.00%
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $1.05
Upside: +471.43%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $12.88
Upside: +327.02%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $4.36
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.42
Upside: +1,791.25%
Dec 18, 2019
Initiates: Buy
Price Target: $600
Current: $2.85
Upside: +20,952.63%